Market Highlights From CapitalHeight.

Apart from relatively stable diesel and petrol prices, car buyers in India have one more reason to cheer, at least for the time being. In a departure from the previous trend, most passenger vehicle makers have refrained from going for an immediate price hike of even as key raw material costs including steel, aluminium, and copper, have risen sharply recently. This is despite the fact that most companies have seen a good volume run, which gives them enough power to introduce price hikes. Passenger vehicle sales in India rose 7.8 per cent to 3.2 million in 2018-19, according to Society of Indian Automobile Manufacturer (SIAM). But most, including volume car makers Maruti Suzuki India and Hyundai Motor India, have chosen to absorb input costs increase, at least for the time being. For More Market Update Click here: CapitalHeight.

    Disappointed over losing the race to acquire Fortis Healthcare, Malaysia's IHH Healthcare said today that it is currently evaluating options while seeking support from shareholders of the Indian firm.IHH Healthcare Managing Director and CEO Tan See Leng claimed that his company's bid offered the highest price and most comprehensive solution and addressed the short-term liquidity requirements and long-term strategic objectives of Fortis. "We are disappointed by the decision made by the Board of Fortis, as we believe we submitted the most compelling bid for the benefit of all Fortis stakeholders," he said in a statement.

Shares of select pharmaceutical companies were under pressure, falling by up to 6% ahead of US President Donald Trump speech today about controlling prescription drug prices.Sun Pharmaceutical Industries slipped 6% to Rs 468 on the BSE in noon deal on back of heavy volumes. Novartis India, Marksans Pharma, Ajanta Pharma, Morepen Laboratories, Alkem Laboratories, Sun Pharma Advanced Research Company (SPARC) and Aarti Drugs were down in the range 3% to 4% on the BSE. For 2 Days Free Trial click here: CapitalHeight.